• It is the main result of the study by the SEN in 2008, which contrasts with the previous survey in 2005 that the Internet was consulted by only 9% of the Spanish population
• The survey confirms a double trend: the emergence of new technologies in the field of health information and the importance that society gives to education and information on health issues
• Therefore, the Spanish Society of Neurology bet on digital media and communication as a tool for all public know first hand these diseases and improve their prevention and treatment and eliminate the stigma experienced by patients
• Only 18% of Canadian respondents said they had gone to a neurologist throughout his life despite the high prevalence of neurological disorders. Stroke, for example, is the leading cause of death among women in our country
In pursuance of the objectives of the Spanish Society of Neurology to spread awareness of neurological diseases and neuroscience, has a population survey conducted shows that the fact that "2 out of 10 Spaniards who participated in the study identified the Internet as means to search for information on neurological diseases. " And although the percentage is 70% far he go to a family doctor for information, the double trend which has been observed in recent times is the emergence of new technologies in the field of health information and the importance that society gives to education and information on health topics.
Furthermore, according to the survey of SEN, only 18% of respondents said they had gone to a neurologist throughout his life. And among those who reported having visited a neurologist at some time, 33% report having made the visit less than 1 year, followed by 28% who indicated having visited the neurologist "for over 5 years." These data contrast, however, with the trend in the incidence and importance of neurological diseases have had in recent years. According to the impact of social and neurological diseases in Spain, the Fund. Spanish Neurological Disease, it is estimated that between 6 and 7.5 million people suffer from a neurological disease, and is a factor that grows each year due to an aging population and increased life expectancy by reducing mortality other diseases.
The poll, conducted for SEN by the Research Institute in 2008, aims at determining the degree of knowledge that society has about neurological diseases, conferred upon him the severity, how often they visit rioja andalusia neurologist or specialist who wait among other things. The aim of the SEN is also able to compare data from this survey with in 2005 to determine whether the changes that are experienced in the perception of society are at the same rate as the incidence and evolution of disease neurological.
To present the findings of the survey chose the SEN framework of its 60th Annual Meeting, considered the most important forum for the Society promotes the dissemination of key developments and progress in the field of neurology. Below are the results of the study in relation to different variables:
Person or means of obtaining information about neurological diseases
The highlight here is the emergence of the internet as a half to find information on neurological diseases, as compared to the survey by the SEN in the year 2005, this item appeared in 9%. Three years ago, the doctor was the first source in 77% of cases, highlighting the primary care and family-only 6% of respondents.
2008 survey data .-
• Although the doctor stresses (mainly the family) as the person that would be used primarily to report certain neurological diseases (including 7 out of 10 interviewees mentioned the figure of the doctor), the Internet has broken so reaching the level of 23%. He continues, although by far the relatives (6%) as the person or means of obtaining information about neurological disorders.
• For ages, the proportion using the internet has risen among young people. Specifically 35% of respondents between 18 and 24 years as highlighted as a potential means of information.
• Stresses are so significant that people in the Northwest and the East in a percentage greater than 80% decided to go to the doctor for information.
• Family members receive a greater number of mentions among the residents of the North (23%) compared with other regions of Spain.
• Among different doctors cited clearly states the doctor followed by the neurologist. Likewise, among the Internet highlight Google as the main vehicle for finding information, and among family members are named in a greater degree cousins and brothers.
Frequency of visits to the Neurologist
Variable in this study, it is important to note the low percentage of visits to the neurologist, since only 18% of respondents claim to have visited the Neurologist's ever in your life. This percentage is significantly higher visitation in men (22% vs. 14%). Similarly, the percentage of visits was higher among young people aged 18-24 (25%), and data that contradicts the widespread perception that neurological diseases are unique to the "elderly" - and those between 55-64 years (22%), those of lower middle class / low (21%) and residents of the Northeast (25%) and South (25%).
This contrasts, however, the fact that neurological diseases have increased in incidence and importance. Cerebrovascular disease incidence has increased in recent times due to the aging of the population: if in 2003 the prevalence of stroke in patients older than 65 years was 7.5%, indicating the expectation that 2030 will be 742,500 patients in Spain and 2050 would be 1,129,000, according to the latest report from the Spanish Foundation for Neurologic Diseases (FEEN).
2008 survey data .-
• Among those who indicated having visited the Neurologist on occasion, 33% report having made the visit less than 1 years and they are followed by those who claim to have made the visit for over 5 years (28%).
• They come to be people between 35-44 years who have most recently visited the neurologist, as well as those of middle and middle class residents in the East (56%).
• On the lower frequency of visits, it stands out among people 45-54 years (60%) and inhabitants of the South (35%.
• The main reason for the visit to the Neurologist consultation relates to the treatment of headache (19%), followed by migraine (17%).
• Are people from 55 to 64 years in which a higher percentage of subjects attending Headache (46%) and migraine (36%). Also, the headaches have a greater impact in the Northeast (27%) and Northwest (29%), while migraines are mentioned more in the center (31%).
• The main route by which it reaches the Neurologist is through the GP, as indicated by half of people who claim to have seen the neurologist. This was followed by the respondent's own decision to go to consultation (15%) and because they come from prescribed emergencies (14%).
• Access from the GP has the greatest effect among those respondents aged 55-64 (73%) residents in the South Peninsula (70%) and those of upper class / upper middle (67%).
• It is among the inhabitants of the Northeast where his own decision to visit a Neurologist is strongest (27% recall).
Awareness of disease
This variable, called attention to change considerably to knowledge of neurological diseases has been experienced among respondents with regard to the latest survey conducted by the SEN in the year 2005. Currently, Alzheimer's and Parkinson are among the five best-known diseases while in 2005 only came with Alzheimer's disease such as cancer or depression.
2008 survey data .-
• Among the most famous include the Cancer and Alzheimer's disease, where 95% and 94% respectively demonstrate their knowledge of these diseases. A follow them notoriety as a percentage of depression (93% of knowledge), osteoarthritis (91%) and Parkinson (90%).
• When considering only the degree of awareness of neurological diseases, Alzheimer's disease becomes better known (94%), followed by Parkinson (90%) and migraine (87%).
• Although cancer is the most well known disease, by age group highlights that in the groups 35-44 years and 55-64 years of Alzheimer's has greater knowledge, even beyond the cancer and even in this last group Depression of 55-65 to be the best known disease.
Specialist to be used for that type of disease
This section is where you can see one of the most notable changes with respect to the 2005 survey. At that time, only 16% of respondents come from a neurologist to treat diseases such as multiple sclerosis and even surprising answers as to 39% would turn to to deal with this trauma disorder of the nervous system directly and 38% do not know what kind consult. Currently, in the 2008 survey, participants referred to the neurologist have all those diseases of neuronal character. This was followed in the family doctor endorsements.
2008 survey data .-
• Based on all those who have referred to a specialist neurologist who would resort to any of the mentioned types of disease, it is clear that Alzheimer's is where more people would turn from a neurologist (68%), followed by Parkinson ( 58%) and migraine (55%).
• Among the neurological diseases, the MS would be one in which there is less association with the figure of the neurologist, and we find that only 30% would come from a neurologist.
Consideration of the level of severity of neurological disease
In the earlier study, the neurological disease is more serious consideration for respondents was multiple sclerosis, although not known to the specialist who treated with a level of severity of 6.6 on 7 (very severe), almost equal to the severity of the cancer. The new data show that stroke, which is currently the leading cause of death among women, has become the neurological disorder is considered more serious.
2008 survey data .-
• Cancer is a disease considered to be more serious, with an average severity of 6.62 points on a scale from 1 (nothing serious) to 7 (very severe).
• When Cancer is still the level of seriousness with a stroke average of 6.48 and 6.42 of an Alzheimer half seriously.
• Migraines (4.72) and headaches (4.47) are less serious in those types of opinions the interviewees.
• Considering only the nature of neurological diseases, stroke, as discussed above, is considered to be the most serious disease, followed by Alzheimer (6.42 seriousness about 7 points), the MS (6.32) and dementia (6.01 ).
• Although there are no significant differences, it is seen that stroke has a greater impact on severity among women (6.53), those aged 18-24 (6.60), the middle class and low-low (6.60 ) and residents in the South (6.57).
VARIABLES TO HIGHLIGHT
Ratings Neurólogo Vs Other Specialties
• In assessing the specialty of Neurólogo, almost half of those aware of the existence of that particular value as excellent or very good, that percentage rises to 64% if one considers also those that give a good assessment. On a scale of 1-7, the average value is about 5.70 points.
• Only 4% rate the specialty of Neurology as bad or very bad.
• When positioning andalusia Neurólogo compared to others, it would occupy the second position value (average of 5.70 points out of 7) below the trauma (average 5.72) and above other specialists such as the oncologist, ophthalmologist, gynecologist etc..
• Although there are no significant differences, it is women who give an average higher than for men (5.74 to 5.65 for men) and those with 55 and 64 years (5.72).
• In class, out of the middle class and low-low as those that give a higher rating (5.95). They are residents in the Northeast (6.12), South (5.93) and Central (5.80) which have a view of the most valued Neurólogo compared to Northern (4.35).
Expectations and Assessment of Neurologist
• Among the different aspects that are expected to accomplish in the course of visiting the neurologist, include the proper treatment (37% of mentions), followed by the solution to problems (30%) and do everything possible to heal andalusia sick (22%).
• Regarding the priority areas worth a visit to the neurologist, two stand above the rest like the fact that Neurólogo relieve the symptoms of the disease and help prevent disease, both with 27% recall.
Awareness of Neurology
• When asked about the degree of knowledge about the specialty of neurology, 28% of spontaneously mentioned, that percentage rises to 69% when it is suggested that specialty, positioning itself as the first known specialty suggested above other specialties such as rheumatology, gynecology, oncology, etc..
• Considering the total number of mentions (spontaneous + suggested), neurology represents the second most famous specialty of cardiology behind, namely the 82% refers to the specialty of Neurology.
• They come to be aged between 18 and 24 years (87%) and those 35-44 years (87%) which have greater visibility of the specialty of Neurology. Similarly, it is the residents in the East (85%) and South Peninsula (90%) who have greater knowledge.
Source information neurologist and / or neurological diseases
• The principal means by which it is aware of the figure of the neurologist and / or neurological diseases is represented by the family, mentioned in 50% of cases. Followed by information obtained through the doctor (18%) and television, with 15% recall.
• women who are at a significantly higher percentage of men to have consistency across the family (56% vs. 45%). They are people between 25-34 years (57%) and residents of the Northwest (62%) who have also learned through the family.
• The doctor is strongest among young people aged 18-24 (31%) and inhabitants of the North (34%) and television among those 45-54 and 65 and over (19%) and inhabitants of Central and Northeast (19%).
• For that point the doctor as a vehicle of information, names the doctor, followed by the neurologist and specialist in general.
TECHNICAL SURVEY
• Universe: Men and women 18 and older.
• Scope: National level by Nielsen Region (Northwest, Northeast, North, Central, South and East) and habitat size (up to 50,000 inhab. / / 50.001-200.000 / / 200.001-500.000 / / more than 200,000)
• Camp dates: June 2008.
• Sample size: 400n. Interview: Telephonic by CATI system (Computer Assisted Personal Interview
• Sampling: Random stratified multistage Nielsen region, province and size of habitat, by telephone households and individuals by sex and age quotas.
• Responsible Institute: RESEARCH S.A. Member AEDEMO, ESOMAR, The Gallup Organization and received the International Code of Ethics ICC / ESOMAR Marketing and Social Research.
Saturday, February 14, 2009
A practical manual of editorial Eduforma MAD offers the keys to living with epilepsy, one of the most common neurological disorders.
The book includes hundreds of questions and answers about a disorder that affects more than 400,000 people in Spain and addresses the issues that patients and families often ask to live with epilepsy
The manual contains specific sections on the impact of the disease in women, children and the elderly, or how to act before an attack
Publishing andaluza reinforces this release with the creation of the web www.mad.es / epilepsy, detailing the work and its author, Anuradha Singh, a specialist at the University of New York
What are the consequences of an epileptic fit? And the risk factors that trigger it? Editorial Eduforma MAD has the answers to these and other issues in his book 100 Questions and answers about epilepsy, a practical manual on one of the most common neurological disorders in the world, only in Spain that affects approximately 400,000 people diagnosed with an incidence of 20,000 new cases annually.
This title Anuradha Singh, a specialist in prestige in the United States collects a hundred questions and answers about the disease, with a strong interest to patients and families affected. The author works in the Global Epilepsy Center, Faculty of Medicine, New York University and is director of the Epilepsy Clinic of the prestigious Bellevue Hospital. The claims that poured into this book answer questions that patients will make in daily practice and helps them to live with this disorder.
The book addresses the disease in three stages, to meet the information needs of each group. Based on each stage of the life cycle of the person diagnosed, the book poses solutions to the childhood to adulthood, with particular attention to the particularities of female-and elderly. Also addresses the various phases of this disorder, ranging from basic studies of diagnosis made by doctors to decide whether or not a patient has epilepsy, to which there are different antiepileptic drugs and their side effects.
Those interested in knowing about this disease will find in this book of the Collection of Health and Family Eduforma Editorial MAD, a real and accessible information on aspects such as symptoms of this disorder, the characteristics of an epileptic fit and first aid if an episode of this type, among other issues of interest to a better understanding of epilepsy.
To reinforce this release, MAD Eduforma Publishing has created a website with details on the contents of the book and its author can be consulted at the address www.mad.es / epilepsy
About MAD Eduforma Editorial
Editorial MAD Eduforma has an experience of over 26 years in publishing books with a practical orientation. Gradually has enriched its extensive catalog to create different collections such as the Health and Family, which owns the book 100 Questions and answers about epilepsy, including titles like 100 questions and answers about asthma in children or 100 questions and answers about psoriasis.
The manual contains specific sections on the impact of the disease in women, children and the elderly, or how to act before an attack
Publishing andaluza reinforces this release with the creation of the web www.mad.es / epilepsy, detailing the work and its author, Anuradha Singh, a specialist at the University of New York
What are the consequences of an epileptic fit? And the risk factors that trigger it? Editorial Eduforma MAD has the answers to these and other issues in his book 100 Questions and answers about epilepsy, a practical manual on one of the most common neurological disorders in the world, only in Spain that affects approximately 400,000 people diagnosed with an incidence of 20,000 new cases annually.
This title Anuradha Singh, a specialist in prestige in the United States collects a hundred questions and answers about the disease, with a strong interest to patients and families affected. The author works in the Global Epilepsy Center, Faculty of Medicine, New York University and is director of the Epilepsy Clinic of the prestigious Bellevue Hospital. The claims that poured into this book answer questions that patients will make in daily practice and helps them to live with this disorder.
The book addresses the disease in three stages, to meet the information needs of each group. Based on each stage of the life cycle of the person diagnosed, the book poses solutions to the childhood to adulthood, with particular attention to the particularities of female-and elderly. Also addresses the various phases of this disorder, ranging from basic studies of diagnosis made by doctors to decide whether or not a patient has epilepsy, to which there are different antiepileptic drugs and their side effects.
Those interested in knowing about this disease will find in this book of the Collection of Health and Family Eduforma Editorial MAD, a real and accessible information on aspects such as symptoms of this disorder, the characteristics of an epileptic fit and first aid if an episode of this type, among other issues of interest to a better understanding of epilepsy.
To reinforce this release, MAD Eduforma Publishing has created a website with details on the contents of the book and its author can be consulted at the address www.mad.es / epilepsy
About MAD Eduforma Editorial
Editorial MAD Eduforma has an experience of over 26 years in publishing books with a practical orientation. Gradually has enriched its extensive catalog to create different collections such as the Health and Family, which owns the book 100 Questions and answers about epilepsy, including titles like 100 questions and answers about asthma in children or 100 questions and answers about psoriasis.
The fixed-dose combination of an inhibitor with amlodipine SRA offers patients better cardiovascular protection than the combination with a diuretic.
Accomplish is the first study that compares results of fixed-dose combinations of an inhibitor of the renin angiotensin system (RAS) to reduce the episodes cardiovasculares1
The combination of a RAS inhibitor with amlodipine reduced by 20% the risk of cardiovascular events in high risk patients, compared with the combination of an inhibitor of the RAS with diurético1
The results accomplished, published in New England Journal of Medicine, show that with fixed-dose combinations, approximately twice of patients achieved the target blood pressure than with previous monotherapy or politerapias1
Patients treated with each of the fixed-dose combinations achieved a mean systolic blood pressure of 130 mmHg1
Accomplish the final results of the first study comparing fixed-dose combinations of antihypertensive drugs in reducing cardiovascular events (CV) have shown that an inhibitor of the renin-angiotensin system (RAS), benazepril combined with amlodipine reduced BESILATE BESYLATE of 20 % CV events such as myocardial infarction and stroke in hypertensive patients at high risk, compared with a combination of RAS inhibitor with hydrochlorothiazide (HCT) 1
The results of accomplish (Avoiding Cardiovascular Events through Combination Therapy in Patients Living With systolic Hypertension; Avoiding cardiovascular events with combination therapy in patients with systolic hypertension), published today in The New England Journal of Medicine, show that some patients were able to double the target blood pressure with a fixed-dose combination compared with their previous antihypertensive treatment, irrespective of whether they were alone or politerapia.1
At the start of the study, only 37% of patients met the target of systolic pressure <140 mmHg.1 After switching to a fixed-dose combination, 72% (combination with HCT) and 75% (combination with amlodipine) of patients achieved the target blood pressure at the end of the trial, with a mean value of systolic pressure of 130 mmHg.1
It is the first study results in a large scale and achieves a value of pressure sistólica.1 systolic blood pressure is a measure of the maximum force exerted against the heart beats when the glasses. This result is very significant because the systolic pressure increases with age and is an important indicator of the risk that a person present episodes CV.2 Indeed, hypertension (HTA) is one of the most important risk factors, but treatable of CV disease (the leading cause of death worldwide) 3
Experience says Barrios, a cardiologist at the Hospital Ramón y Cajal de Madrid, accomplish results open interesting new perspectives on the utility of using fixed combinations in the initial treatment of hypertension in high risk patients, unlike the monotherapy, which is what usually does. "
The cardiologist noted that Barrios Experience the study reached an excellent level in controlling the numbers of blood pressure in more than 72% of patients at high risk. "
Examples of inhibitors of the SRA are receptor antagonists of angiotensin (ARA-II, such as valsartan (Diovan ®) and inhibitors of angiotensin converting enzyme (ACE inhibitors such as benazepril). It has been observed that through inhibition of RAS with a single O-II or an ACE inhibitor reduces episodes CV.4-7 However, more than half of hypertensive patients may need polytherapy to achieve the goals of pressure arterial.8
Patients may have greater compliance, if they take their medication in a single tablet that when there are two different tablets, 9 but so far there had been no test results that support the early use of fixed-dose combinations in the course treatment. On accomplished, half the patients achieved their goal of taking blood pressure medication in a single tablet, ie without any treatment adicional.10 addition, approximately 70% of patients taking the combination at the end of estudio.1
The two fixed-dose combinations were well tolerated. The incidence of adverse events that led to the withdrawal of the study was low, approximately 15% of both groups and only 0.5% (combination with HCT) and 0.4% (combination with amlodipine) experienced adverse events such as hypotension grave.1
"For patients with hypertension who need simple and effective therapeutic strategies to help reduce the risk of CV events, the results indicate that accomplish a fixed-dose combination of an RAS inhibitor and amlodipine is an effective option, well tolerated and convenient, "said Dr. Ameet Nathwani, director of international franchise development and Cardiovascular Metabolism Novartis Pharma AG.
Novartis' confidence in the strategy of fixed-dose combination is reflected in the success of two of its antihypertensive: Exforge ®, the first fixed combination of valsartan and amlodipine and Co-Diovan ® (Diovan plus hydrochlorothiazide). Both Exforge ® as Co-Diovan ® has been recently approved in USA for first-line use in patients likely to require polytherapy to achieve their goal blood pressure. Exforge ® is a new combination therapy (valsartan and amlodipine), which gives patients the opportunity to better control your blood pressure and allows for greater tolerability and adherence to treatment. In Spain, Exforge ® is indicated in patients whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy, while Co-Diovan ® is indicated in patients whose blood pressure is not adequately controlled with valsartan monotherapy.
Novartis is dedicated to improving the lives of hundreds of millions of people with CV and metabolic diseases through medicines and effective programs, and its continued commitment to research. As a global leader in CV and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat hypertension and diabetes, two major public health problems.
The product portfolio Novartis is focused on drugs for cardiovascular disease, specifically for the treatment of hypertension and diabetes: Exforge ®, and Co-Diovan ® and Diovan ® Rasilez ® (aliskiren) the first and only direct inhibitor renin and authorized a new DPP-4 inhibitor Galvus ® (vildagliptin, which is also available as a fixed dose combination with metformin, Eucreas ®).
About accomplish
Accomplish is a test based on events, multicenter, multinational, randomized, double blind, which has involved more than 11,000 patients from 550 centers around the U.S. and Scandinavian countries. The evaluation criteria included composite of myocardial infarction, stroke, hospitalizations for unstable angina pectoris and CV death in hypertensive patients at high risk. This is the first test results in a CV hypertensive population, in which all patients were randomized to receive a fixed-dose combination therapy at the beginning of the test rather than a therapeutic staggered pattern. Patients received a fixed dose combination of an RAS inhibitor (benazepril) with BESILATE BESYLATE of amlodipine or same RAS inhibitor with HCT. In the first 2 months of the study, increased doses of drugs for study: the inhibitor of the renin-angiotensin system was increased gradually to 40 mg and subsequently in patients who did not achieve the target blood pressure was increased gradually HCT 25 mg and amlodipine 10 mg.
Bibliography
1 Jamerson K et al. Or Amlodipine Benazepril plus hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med 2008, 359:2417-28.
2 Williams B et al. Systolic pressure is all that matters. Lancet 2008, 371:2219-21.
3 World Health Organization. Cardiovascular Disease Factsheet. Accessed:
http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
4 Yusuf S et al. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
high risk patients. N Engl J Med 2000, 342:145-53.
5 Fox KM et al. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable
coronary artery disease, randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet 2003; 362:782-8.
6 Cohn J et al. A randomized trial of the angiotensin-receptor-blocker valsartan in chronic heart failure. N
Engl J Med 2001, 345:1667-75.
7 Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left
ventricular dysfunction, or both. N Engl J Med 2003; 349 (20) :1893-906.
8 Dahlöf B et al. Prevention of cardiovascular events with an Antihypertensive regimen of adding Amlodipine
Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized
controlled trial. Lancet 2005, 366:895-906
9 Arshad S et al. Comparison of effectiveness and safety of fixed-dose combinations of Antihypertensive
agents with the free-drug combination of its components when given separately in hypertensive patients: a
meta-analysis of 32 134 patients. J Human Hypertens 2008, 22: S1-S12. Abstract # 5.3.
10 Jamerson KA. Accomplish Late Breaking Presentation at ACC, March 31, 2008.
The combination of a RAS inhibitor with amlodipine reduced by 20% the risk of cardiovascular events in high risk patients, compared with the combination of an inhibitor of the RAS with diurético1
The results accomplished, published in New England Journal of Medicine, show that with fixed-dose combinations, approximately twice of patients achieved the target blood pressure than with previous monotherapy or politerapias1
Patients treated with each of the fixed-dose combinations achieved a mean systolic blood pressure of 130 mmHg1
Accomplish the final results of the first study comparing fixed-dose combinations of antihypertensive drugs in reducing cardiovascular events (CV) have shown that an inhibitor of the renin-angiotensin system (RAS), benazepril combined with amlodipine reduced BESILATE BESYLATE of 20 % CV events such as myocardial infarction and stroke in hypertensive patients at high risk, compared with a combination of RAS inhibitor with hydrochlorothiazide (HCT) 1
The results of accomplish (Avoiding Cardiovascular Events through Combination Therapy in Patients Living With systolic Hypertension; Avoiding cardiovascular events with combination therapy in patients with systolic hypertension), published today in The New England Journal of Medicine, show that some patients were able to double the target blood pressure with a fixed-dose combination compared with their previous antihypertensive treatment, irrespective of whether they were alone or politerapia.1
At the start of the study, only 37% of patients met the target of systolic pressure <140 mmHg.1 After switching to a fixed-dose combination, 72% (combination with HCT) and 75% (combination with amlodipine) of patients achieved the target blood pressure at the end of the trial, with a mean value of systolic pressure of 130 mmHg.1
It is the first study results in a large scale and achieves a value of pressure sistólica.1 systolic blood pressure is a measure of the maximum force exerted against the heart beats when the glasses. This result is very significant because the systolic pressure increases with age and is an important indicator of the risk that a person present episodes CV.2 Indeed, hypertension (HTA) is one of the most important risk factors, but treatable of CV disease (the leading cause of death worldwide) 3
Experience says Barrios, a cardiologist at the Hospital Ramón y Cajal de Madrid, accomplish results open interesting new perspectives on the utility of using fixed combinations in the initial treatment of hypertension in high risk patients, unlike the monotherapy, which is what usually does. "
The cardiologist noted that Barrios Experience the study reached an excellent level in controlling the numbers of blood pressure in more than 72% of patients at high risk. "
Examples of inhibitors of the SRA are receptor antagonists of angiotensin (ARA-II, such as valsartan (Diovan ®) and inhibitors of angiotensin converting enzyme (ACE inhibitors such as benazepril). It has been observed that through inhibition of RAS with a single O-II or an ACE inhibitor reduces episodes CV.4-7 However, more than half of hypertensive patients may need polytherapy to achieve the goals of pressure arterial.8
Patients may have greater compliance, if they take their medication in a single tablet that when there are two different tablets, 9 but so far there had been no test results that support the early use of fixed-dose combinations in the course treatment. On accomplished, half the patients achieved their goal of taking blood pressure medication in a single tablet, ie without any treatment adicional.10 addition, approximately 70% of patients taking the combination at the end of estudio.1
The two fixed-dose combinations were well tolerated. The incidence of adverse events that led to the withdrawal of the study was low, approximately 15% of both groups and only 0.5% (combination with HCT) and 0.4% (combination with amlodipine) experienced adverse events such as hypotension grave.1
"For patients with hypertension who need simple and effective therapeutic strategies to help reduce the risk of CV events, the results indicate that accomplish a fixed-dose combination of an RAS inhibitor and amlodipine is an effective option, well tolerated and convenient, "said Dr. Ameet Nathwani, director of international franchise development and Cardiovascular Metabolism Novartis Pharma AG.
Novartis' confidence in the strategy of fixed-dose combination is reflected in the success of two of its antihypertensive: Exforge ®, the first fixed combination of valsartan and amlodipine and Co-Diovan ® (Diovan plus hydrochlorothiazide). Both Exforge ® as Co-Diovan ® has been recently approved in USA for first-line use in patients likely to require polytherapy to achieve their goal blood pressure. Exforge ® is a new combination therapy (valsartan and amlodipine), which gives patients the opportunity to better control your blood pressure and allows for greater tolerability and adherence to treatment. In Spain, Exforge ® is indicated in patients whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy, while Co-Diovan ® is indicated in patients whose blood pressure is not adequately controlled with valsartan monotherapy.
Novartis is dedicated to improving the lives of hundreds of millions of people with CV and metabolic diseases through medicines and effective programs, and its continued commitment to research. As a global leader in CV and metabolic health for nearly 50 years, Novartis provides innovative therapies and support programs to treat hypertension and diabetes, two major public health problems.
The product portfolio Novartis is focused on drugs for cardiovascular disease, specifically for the treatment of hypertension and diabetes: Exforge ®, and Co-Diovan ® and Diovan ® Rasilez ® (aliskiren) the first and only direct inhibitor renin and authorized a new DPP-4 inhibitor Galvus ® (vildagliptin, which is also available as a fixed dose combination with metformin, Eucreas ®).
About accomplish
Accomplish is a test based on events, multicenter, multinational, randomized, double blind, which has involved more than 11,000 patients from 550 centers around the U.S. and Scandinavian countries. The evaluation criteria included composite of myocardial infarction, stroke, hospitalizations for unstable angina pectoris and CV death in hypertensive patients at high risk. This is the first test results in a CV hypertensive population, in which all patients were randomized to receive a fixed-dose combination therapy at the beginning of the test rather than a therapeutic staggered pattern. Patients received a fixed dose combination of an RAS inhibitor (benazepril) with BESILATE BESYLATE of amlodipine or same RAS inhibitor with HCT. In the first 2 months of the study, increased doses of drugs for study: the inhibitor of the renin-angiotensin system was increased gradually to 40 mg and subsequently in patients who did not achieve the target blood pressure was increased gradually HCT 25 mg and amlodipine 10 mg.
Bibliography
1 Jamerson K et al. Or Amlodipine Benazepril plus hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med 2008, 359:2417-28.
2 Williams B et al. Systolic pressure is all that matters. Lancet 2008, 371:2219-21.
3 World Health Organization. Cardiovascular Disease Factsheet. Accessed:
http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
4 Yusuf S et al. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in
high risk patients. N Engl J Med 2000, 342:145-53.
5 Fox KM et al. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable
coronary artery disease, randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet 2003; 362:782-8.
6 Cohn J et al. A randomized trial of the angiotensin-receptor-blocker valsartan in chronic heart failure. N
Engl J Med 2001, 345:1667-75.
7 Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left
ventricular dysfunction, or both. N Engl J Med 2003; 349 (20) :1893-906.
8 Dahlöf B et al. Prevention of cardiovascular events with an Antihypertensive regimen of adding Amlodipine
Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized
controlled trial. Lancet 2005, 366:895-906
9 Arshad S et al. Comparison of effectiveness and safety of fixed-dose combinations of Antihypertensive
agents with the free-drug combination of its components when given separately in hypertensive patients: a
meta-analysis of 32 134 patients. J Human Hypertens 2008, 22: S1-S12. Abstract # 5.3.
10 Jamerson KA. Accomplish Late Breaking Presentation at ACC, March 31, 2008.
A new model for streamlining and improving the quality of death certificates.
• There will be only to fill a single form for the certification of death for registration for statistical purposes. Enter into force next January 1 and will be distributed, as now, through the Colleges of Physicians
The National Statistics Institute (INE) and the General Council of Colleges of Physicians (CGCOM) have reached an agreement to launch a new set of "Medical Certificate of Death / Death Statistics Bulletin," so as to delete the current task being undertaken by doctors in this area and have a unique tool used to register both functions. This implies not only a breakthrough in the simplification of tasks but also in improving quality.
Currently, the law distinguishes between the death registration and certification thereof. In this way, the task of certifying doctors was doubled because of a party must certify the death in the corresponding medical certificate of death and otherwise, have to fill in the section on causes of death in the Statistical Bulletin of Deaths .
There are two official statistics on deaths, compiled by the INE: Natural Movement of Population (births, deaths, marriages) and Deaths by cause of death. For both statistics using the Statistical Bulletin of Deaths, part of which-in particular on the causes of death-to be completed by the medical certifier. For his part, CGCOM as Public Law Corporation, is the only body authorized to edit and distribute the forms of medical officers, including the medical certificate of death "will be used to prove that, with the requirements and impacts identified in existing laws and regulations. "
Therefore, given the need to eliminate this task and establish a new form of more rapid and effective action, within the competences of each part, and NSIs CGCOM have agreed to produce and edit a new set of Certified Doctor Death and Statistical Bulletin in order to provide a single document for both the registration of death in the Civil Registry to compile statistics of the Natural Movement of Population.
The new series will run for instructions for death to occur in the civil registers from January 1 2009 and will CGCOM distribution through the Colleges of Physicians in the same way as is being done in currently with the medical certificate of death.
The signing of the agreement and presentation has been delivered by the Chairman of the National Institute of Statistics, Jaume García Villar and Vice President of the General Council of Medical Colleges, Ricard Gutierrez in a ceremony held at the headquarters of the Medical School.
Quality and certification
Certification is a medical act, subject to the requirements contained in the statutory and ethical standards of the Medical College Organization (WTO), and in particular to the provisions of Title VI of the General Statutes (art.58-61) and in the current Code of Ethics and Medical Ethics of the Medical College Organization (Article 11). The medical certificate of death is a document subject to the rules of professional responsibility. CERTIFY clause in the medical report gives you the value of a legally-certified and as such, public document and provides a supplement to its content testimonial guarantee and commitment.
Considering the importance of death certificates to understand the causes of death and its determinants, the WTO will initiate an immediate update of a training strategy to improve the quality and content of certificates.
The National Statistics Institute (INE) and the General Council of Colleges of Physicians (CGCOM) have reached an agreement to launch a new set of "Medical Certificate of Death / Death Statistics Bulletin," so as to delete the current task being undertaken by doctors in this area and have a unique tool used to register both functions. This implies not only a breakthrough in the simplification of tasks but also in improving quality.
Currently, the law distinguishes between the death registration and certification thereof. In this way, the task of certifying doctors was doubled because of a party must certify the death in the corresponding medical certificate of death and otherwise, have to fill in the section on causes of death in the Statistical Bulletin of Deaths .
There are two official statistics on deaths, compiled by the INE: Natural Movement of Population (births, deaths, marriages) and Deaths by cause of death. For both statistics using the Statistical Bulletin of Deaths, part of which-in particular on the causes of death-to be completed by the medical certifier. For his part, CGCOM as Public Law Corporation, is the only body authorized to edit and distribute the forms of medical officers, including the medical certificate of death "will be used to prove that, with the requirements and impacts identified in existing laws and regulations. "
Therefore, given the need to eliminate this task and establish a new form of more rapid and effective action, within the competences of each part, and NSIs CGCOM have agreed to produce and edit a new set of Certified Doctor Death and Statistical Bulletin in order to provide a single document for both the registration of death in the Civil Registry to compile statistics of the Natural Movement of Population.
The new series will run for instructions for death to occur in the civil registers from January 1 2009 and will CGCOM distribution through the Colleges of Physicians in the same way as is being done in currently with the medical certificate of death.
The signing of the agreement and presentation has been delivered by the Chairman of the National Institute of Statistics, Jaume García Villar and Vice President of the General Council of Medical Colleges, Ricard Gutierrez in a ceremony held at the headquarters of the Medical School.
Quality and certification
Certification is a medical act, subject to the requirements contained in the statutory and ethical standards of the Medical College Organization (WTO), and in particular to the provisions of Title VI of the General Statutes (art.58-61) and in the current Code of Ethics and Medical Ethics of the Medical College Organization (Article 11). The medical certificate of death is a document subject to the rules of professional responsibility. CERTIFY clause in the medical report gives you the value of a legally-certified and as such, public document and provides a supplement to its content testimonial guarantee and commitment.
Considering the importance of death certificates to understand the causes of death and its determinants, the WTO will initiate an immediate update of a training strategy to improve the quality and content of certificates.
Tuesday, February 10, 2009
Pharmaceutical sector in Turkey
ARAŞTIRMACILAR Pharmaceutical Companies Association (AİFD) Chairman Dr Pharmacists. According to the information Demirdere'nin altan:
Approximately U.S. $ 5.5 billion in consumer prices in Turkey are consumed drugs. On the other hand, annual cigarette consumption in Turkey U.S. $ 8 billion, annual alcohol consumption is 10 billion U.S. $.
This money is spent on medication, both in total and per capita, less than 4 times compared to other countries. Also, compared to other countries, in Turkey there is less drug types. However, total health expenditures in Turkey in the share of drug compared to 2 times more than other countries.
The main reason, drugs are expensive, or not much expenses, total health spending is insufficient. Total health expenditure 8.5% of GDP in other countries' u is lower than in Turkey, although other countries, around 4% of GNP.
Rate in Turkey to meet the pharmaceutical exports and imports is very low and around 10%.
Indian generic drugs produced in the original and almost all of the active substances are being imported from abroad.
17% of the world such as the pharmaceutical sector, the vast majority of turnover research and development expenditures is the only industry. This rate of 10.5% even in computer software, electric-electronic industry 8.4%!
Share in the value of drugs imported from Turkey, some 38%, 12% of box basis. The figures below normal limits in the world. Extremely important as an original and generic pharmaceutical industry in Germany has to pay for imported drugs as 45th%
However, the share of generics in Turkey is around 45% by value, while the European average, and the United States this figure is 30% in value (Germany and the UK is around 20s%).
Clinical Research 40 billion in total spending is $. Our country only 1% of total clinical research in the country in case we can bring $ 400 million be transferred would be possible.
* * *
9th of 19 January 2005 Licensing Regulations According to Article generic drug manufacturers have resisted for years, but the defense insists that the EU 'medicine of data protection' to be applied from this date, our country has been adopted. However, someone from the Ministry of Health and wiliness etmiş According to the figures does not reveal, to some 300 by 1200 according to some generic application is still compressed to.
The EU claims they can not be absolutely license!
Ministry of Health is not yet clear what will!
Secretary-General says Engin Guner AİFD:
'Fictitious claims should not be considered absolutely. Only with all the necessary reports and documents biyoeşdeğerlik report has been submitted to serious consideration of the application-application in 1000, but in short, maybe 20-30 a solution can be found is a serious guarantee application-I am thinking. This is my my opinion.
Thus, the European Court of Justice on the EU's drive to the left in a difficult situation, such as Turkey, I think growth can be prevented. "
* * *
Obviously, Turkey can not escape in a game but still had contact with Ali Cengiz oyunu hand man does not eat!
Approximately U.S. $ 5.5 billion in consumer prices in Turkey are consumed drugs. On the other hand, annual cigarette consumption in Turkey U.S. $ 8 billion, annual alcohol consumption is 10 billion U.S. $.
This money is spent on medication, both in total and per capita, less than 4 times compared to other countries. Also, compared to other countries, in Turkey there is less drug types. However, total health expenditures in Turkey in the share of drug compared to 2 times more than other countries.
The main reason, drugs are expensive, or not much expenses, total health spending is insufficient. Total health expenditure 8.5% of GDP in other countries' u is lower than in Turkey, although other countries, around 4% of GNP.
Rate in Turkey to meet the pharmaceutical exports and imports is very low and around 10%.
Indian generic drugs produced in the original and almost all of the active substances are being imported from abroad.
17% of the world such as the pharmaceutical sector, the vast majority of turnover research and development expenditures is the only industry. This rate of 10.5% even in computer software, electric-electronic industry 8.4%!
Share in the value of drugs imported from Turkey, some 38%, 12% of box basis. The figures below normal limits in the world. Extremely important as an original and generic pharmaceutical industry in Germany has to pay for imported drugs as 45th%
However, the share of generics in Turkey is around 45% by value, while the European average, and the United States this figure is 30% in value (Germany and the UK is around 20s%).
Clinical Research 40 billion in total spending is $. Our country only 1% of total clinical research in the country in case we can bring $ 400 million be transferred would be possible.
* * *
9th of 19 January 2005 Licensing Regulations According to Article generic drug manufacturers have resisted for years, but the defense insists that the EU 'medicine of data protection' to be applied from this date, our country has been adopted. However, someone from the Ministry of Health and wiliness etmiş According to the figures does not reveal, to some 300 by 1200 according to some generic application is still compressed to.
The EU claims they can not be absolutely license!
Ministry of Health is not yet clear what will!
Secretary-General says Engin Guner AİFD:
'Fictitious claims should not be considered absolutely. Only with all the necessary reports and documents biyoeşdeğerlik report has been submitted to serious consideration of the application-application in 1000, but in short, maybe 20-30 a solution can be found is a serious guarantee application-I am thinking. This is my my opinion.
Thus, the European Court of Justice on the EU's drive to the left in a difficult situation, such as Turkey, I think growth can be prevented. "
* * *
Obviously, Turkey can not escape in a game but still had contact with Ali Cengiz oyunu hand man does not eat!
Pharmaceutical sector was met with double-barcode
Automatic identification and data collection industry's leading companies in the world, Turkey distributor Boer Electronics, held on 13-16 November 9th Turkey participated in the Congress of Pharmacy, the couple will enter the year 2009 since the implementation of solutions related to barcode system was introduced.
Be the largest in Turkey with the participation of Congress and 13 - 16 November WOW Hotels & Convention Center on the 9th place in Yesilkoy Turkey Pharmaceuticals meet Congress the Boer Electronics pharmacists, pharmacy stores and pharmacies to be read by barcode Karekod offer the opportunity to promote the different solutions found.
At the beginning of 2009 to be implemented according to the prescribed system, no medicine "secondary identification" (bar code) will not be printed without. Current barcode system, only its own stocks of companies, products, and sales are tracked, 'Dual barcode' system of drug selling, store, export or import of any of pharmacy with all the movement to a centralized system (Drug Tracking System) will be notified.
Be the largest in Turkey with the participation of Congress and 13 - 16 November WOW Hotels & Convention Center on the 9th place in Yesilkoy Turkey Pharmaceuticals meet Congress the Boer Electronics pharmacists, pharmacy stores and pharmacies to be read by barcode Karekod offer the opportunity to promote the different solutions found.
At the beginning of 2009 to be implemented according to the prescribed system, no medicine "secondary identification" (bar code) will not be printed without. Current barcode system, only its own stocks of companies, products, and sales are tracked, 'Dual barcode' system of drug selling, store, export or import of any of pharmacy with all the movement to a centralized system (Drug Tracking System) will be notified.
AİFD: 2008 for the pharmaceutical sector
ISTANBUL (UAV) - Researchers Pharmaceutical Companies Association (AİFD), 2008 an important year for Turkey in the pharmaceutical sector will be made.
AİFD'den made in 2008 on health reform, improve the investment environment and the sector on measures to improve the global competitiveness should be pointed out that serious progress has been.
In 2008 the pharmaceutical sector in Turkey will be an important recording AİFD, Turkey's innovative drug research, development and production as a global power, in other countries of the developed technology and products among the audience of a way to stay in the said separation.
AİFD in 2008 to discover new drugs and to investigate global-scale investment of nearly 70 billion dollars to do that and call for the trial stage of cancer in more than 600 new medicines to the island, more than 6 thousand of new drug candidates under development said.
New production centers, equipment and renovation will be done this year for the investment of billions of dollars is added in 2008 in the innovative pharmaceutical industry about $ 100 billion at the global level, in the amount of investment is expected to be made.
Issues related to evaluating the Secretary-General AİFD Engin Güner, "Turkey in 2008 in the innovative pharmaceutical sector to competition and health sciences in the global investment rather than a greater share of opportunities to catch. However, this decision of a global race and that Turkey's successful compete for the right vision, strategy and policies should be implemented must be able to see a clear way, "he said.
"Turkey for new drugs in 2007 for 1 percent of global investments attract a lower rate than the very advanced stages of clinical research in the direction of funds to the approximately 27 million dollars, only able to receive" says Engin Guner, "from Turkey in total exports of generic and innovative pharmaceutical 350 million the dollar was lower. Turkey's much smaller than Ireland and that of countries like Singapore drug exports billions of dollars to overcome. Ireland's pharmaceutical export chemicals with 50 billion dollars to overcome. This country's domestic drug consumption financing exports rapidly growing support from drug production tax from the to provide, "he spoke.
"2008, a critical year of decision"
Guner, "AİFD, Turkey, Health Sciences is a competitor in the global position as the past 2 years many proposals were submitted. The future to keep things light with innovative medicines and health sciences industry to develop the potential for many constructive activities, and have offered suggestions. Ülkemizin truly first-class quality to have in an innovative pharmaceutical industry is our most important priorities at this stage "as it had not.
Secretary General Engin Güner AİFD sector can reach a more advanced point in the following order of priority objectives are:
"New drugs are licensed from 2-3 years and be paid back in 6-9 months to licensing reform,
Accelerate the process of harmonization with EU standards, waiting a long time, clinical research for the realization of legal arrangements to raise standards, tax incentives,
To attract international investment in Turkey, to investigate innovative drugs, the leading country in production and exports among other measures to ensure access. "
"In Singapore, if a new drug known worldwide, such as FDA and EMEA approval of the organization has received as little as 2 months at a time to be produced and marketed for licenses in Turkey, this time in 2 years can take up to" said the new production Güner evaluate decisions in terms of the company, 2 months and 2 years was the difference between the points to the importance of.
Turkey yaşadığı's brain drain problem attracts the attention Güner, "Our country medicine and science in the field of rich human resources has. But support policies because of the lack of these people, research and development efforts in large part to do abroad. Turkey in more R & D investments to encourage there is a need for new policies, "he said.
In Turkey, the innovative pharmaceutical industry and life sciences in terms of the assessment in 2007 that Güner, "the good way of work in 2007 of the proposed decision to listen more carefully to be started, and Turkey, a world class competitors are seeing could be. However, the investment environment to improve a little more concrete step did not. Yet the world pharmaceutical industry experienced a serious competition does. innovative pharmaceutical industry, Ireland, Singapore, China or India in the ongoing new investments are made. We in our country for the pharmaceutical sector road map for establishing as always, will contribute. our government to us, a critical decision The correct year 2008 and long-term policies to put into practice hope. Ireland or Singapore as models of innovative medicines covered by evaluating and implementing the right policies, Turkey innovative drugs in the new investments may be about 1 billion dollars, "he spoke.
AİFD'den made in 2008 on health reform, improve the investment environment and the sector on measures to improve the global competitiveness should be pointed out that serious progress has been.
In 2008 the pharmaceutical sector in Turkey will be an important recording AİFD, Turkey's innovative drug research, development and production as a global power, in other countries of the developed technology and products among the audience of a way to stay in the said separation.
AİFD in 2008 to discover new drugs and to investigate global-scale investment of nearly 70 billion dollars to do that and call for the trial stage of cancer in more than 600 new medicines to the island, more than 6 thousand of new drug candidates under development said.
New production centers, equipment and renovation will be done this year for the investment of billions of dollars is added in 2008 in the innovative pharmaceutical industry about $ 100 billion at the global level, in the amount of investment is expected to be made.
Issues related to evaluating the Secretary-General AİFD Engin Güner, "Turkey in 2008 in the innovative pharmaceutical sector to competition and health sciences in the global investment rather than a greater share of opportunities to catch. However, this decision of a global race and that Turkey's successful compete for the right vision, strategy and policies should be implemented must be able to see a clear way, "he said.
"Turkey for new drugs in 2007 for 1 percent of global investments attract a lower rate than the very advanced stages of clinical research in the direction of funds to the approximately 27 million dollars, only able to receive" says Engin Guner, "from Turkey in total exports of generic and innovative pharmaceutical 350 million the dollar was lower. Turkey's much smaller than Ireland and that of countries like Singapore drug exports billions of dollars to overcome. Ireland's pharmaceutical export chemicals with 50 billion dollars to overcome. This country's domestic drug consumption financing exports rapidly growing support from drug production tax from the to provide, "he spoke.
"2008, a critical year of decision"
Guner, "AİFD, Turkey, Health Sciences is a competitor in the global position as the past 2 years many proposals were submitted. The future to keep things light with innovative medicines and health sciences industry to develop the potential for many constructive activities, and have offered suggestions. Ülkemizin truly first-class quality to have in an innovative pharmaceutical industry is our most important priorities at this stage "as it had not.
Secretary General Engin Güner AİFD sector can reach a more advanced point in the following order of priority objectives are:
"New drugs are licensed from 2-3 years and be paid back in 6-9 months to licensing reform,
Accelerate the process of harmonization with EU standards, waiting a long time, clinical research for the realization of legal arrangements to raise standards, tax incentives,
To attract international investment in Turkey, to investigate innovative drugs, the leading country in production and exports among other measures to ensure access. "
"In Singapore, if a new drug known worldwide, such as FDA and EMEA approval of the organization has received as little as 2 months at a time to be produced and marketed for licenses in Turkey, this time in 2 years can take up to" said the new production Güner evaluate decisions in terms of the company, 2 months and 2 years was the difference between the points to the importance of.
Turkey yaşadığı's brain drain problem attracts the attention Güner, "Our country medicine and science in the field of rich human resources has. But support policies because of the lack of these people, research and development efforts in large part to do abroad. Turkey in more R & D investments to encourage there is a need for new policies, "he said.
In Turkey, the innovative pharmaceutical industry and life sciences in terms of the assessment in 2007 that Güner, "the good way of work in 2007 of the proposed decision to listen more carefully to be started, and Turkey, a world class competitors are seeing could be. However, the investment environment to improve a little more concrete step did not. Yet the world pharmaceutical industry experienced a serious competition does. innovative pharmaceutical industry, Ireland, Singapore, China or India in the ongoing new investments are made. We in our country for the pharmaceutical sector road map for establishing as always, will contribute. our government to us, a critical decision The correct year 2008 and long-term policies to put into practice hope. Ireland or Singapore as models of innovative medicines covered by evaluating and implementing the right policies, Turkey innovative drugs in the new investments may be about 1 billion dollars, "he spoke.
Subscribe to:
Posts (Atom)
